Haleon plc
Haleon plc HLN Peers
See (HLN) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HLN | $10.45 | -2.43% | 47.13B | 24.88 | $0.42 | +1.60% |
| ZTS | $160.41 | -0.94% | 71.41B | 28.80 | $5.57 | +1.15% |
| TAK | $13.73 | -3.28% | 43.26B | 30.50 | $0.45 | +4.29% |
| TEVA | $17.49 | -2.62% | 20.04B | -15.21 | -$1.15 | N/A |
| ITCI | $131.87 | N/A | 14.05B | -180.64 | -$0.73 | N/A |
| RDY | $14.09 | +1.11% | 11.73B | 18.53 | $0.76 | +0.68% |
| NBIX | $116.87 | -2.96% | 11.57B | 39.48 | $2.96 | N/A |
| CTLT | $63.48 | N/A | 11.52B | -27.84 | -$2.28 | N/A |
| VTRS | $8.79 | -1.90% | 10.32B | -16.58 | -$0.53 | +5.43% |
| ELAN | $13.03 | +1.64% | 6.47B | 17.37 | $0.75 | N/A |
Stock Comparison
HLN vs ZTS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ZTS has a market cap of 71.41B. Regarding current trading prices, HLN is priced at $10.45, while ZTS trades at $160.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ZTS's P/E ratio is 28.80. In terms of profitability, HLN's ROE is +0.09%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, HLN is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TAK Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TAK has a market cap of 43.26B. Regarding current trading prices, HLN is priced at $10.45, while TAK trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TAK's P/E ratio is 30.50. In terms of profitability, HLN's ROE is +0.09%, compared to TAK's ROE of +0.04%. Regarding short-term risk, HLN is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TEVA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TEVA has a market cap of 20.04B. Regarding current trading prices, HLN is priced at $10.45, while TEVA trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TEVA's P/E ratio is -15.21. In terms of profitability, HLN's ROE is +0.09%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, HLN is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ITCI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ITCI has a market cap of 14.05B. Regarding current trading prices, HLN is priced at $10.45, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HLN's ROE is +0.09%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, HLN is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs RDY Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, RDY has a market cap of 11.73B. Regarding current trading prices, HLN is priced at $10.45, while RDY trades at $14.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas RDY's P/E ratio is 18.53. In terms of profitability, HLN's ROE is +0.09%, compared to RDY's ROE of +0.18%. Regarding short-term risk, HLN is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs NBIX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, NBIX has a market cap of 11.57B. Regarding current trading prices, HLN is priced at $10.45, while NBIX trades at $116.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas NBIX's P/E ratio is 39.48. In terms of profitability, HLN's ROE is +0.09%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, HLN is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CTLT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, CTLT has a market cap of 11.52B. Regarding current trading prices, HLN is priced at $10.45, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HLN's ROE is +0.09%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, HLN is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs VTRS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, VTRS has a market cap of 10.32B. Regarding current trading prices, HLN is priced at $10.45, while VTRS trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas VTRS's P/E ratio is -16.58. In terms of profitability, HLN's ROE is +0.09%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, HLN is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ELAN Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ELAN has a market cap of 6.47B. Regarding current trading prices, HLN is priced at $10.45, while ELAN trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ELAN's P/E ratio is 17.37. In terms of profitability, HLN's ROE is +0.09%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LNTH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, LNTH has a market cap of 5.46B. Regarding current trading prices, HLN is priced at $10.45, while LNTH trades at $78.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas LNTH's P/E ratio is 18.11. In terms of profitability, HLN's ROE is +0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, HLN is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs RGC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, RGC has a market cap of 4.22B. Regarding current trading prices, HLN is priced at $10.45, while RGC trades at $324.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas RGC's P/E ratio is -1012.52. In terms of profitability, HLN's ROE is +0.09%, compared to RGC's ROE of -0.25%. Regarding short-term risk, HLN is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PRGO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, PRGO has a market cap of 3.61B. Regarding current trading prices, HLN is priced at $10.45, while PRGO trades at $26.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas PRGO's P/E ratio is -21.85. In terms of profitability, HLN's ROE is +0.09%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, HLN is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AMRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, AMRX has a market cap of 3.49B. Regarding current trading prices, HLN is priced at $10.45, while AMRX trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas AMRX's P/E ratio is -187.50. In terms of profitability, HLN's ROE is +0.09%, compared to AMRX's ROE of -0.00%. Regarding short-term risk, HLN is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ALVO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ALVO has a market cap of 3.19B. Regarding current trading prices, HLN is priced at $10.45, while ALVO trades at $10.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ALVO's P/E ratio is -12.14. In terms of profitability, HLN's ROE is +0.09%, compared to ALVO's ROE of +0.46%. Regarding short-term risk, HLN is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs EVO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, EVO has a market cap of 2.98B. Regarding current trading prices, HLN is priced at $10.45, while EVO trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas EVO's P/E ratio is -6.36. In terms of profitability, HLN's ROE is +0.09%, compared to EVO's ROE of -0.19%. Regarding short-term risk, HLN is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ALVOW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ALVOW has a market cap of 2.92B. Regarding current trading prices, HLN is priced at $10.45, while ALVOW trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ALVOW's P/E ratio is N/A. In terms of profitability, HLN's ROE is +0.09%, compared to ALVOW's ROE of +0.46%. Regarding short-term risk, HLN is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs HCM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, HCM has a market cap of 2.37B. Regarding current trading prices, HLN is priced at $10.45, while HCM trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas HCM's P/E ratio is 65.70. In terms of profitability, HLN's ROE is +0.09%, compared to HCM's ROE of +0.05%. Regarding short-term risk, HLN is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DCPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, DCPH has a market cap of 2.21B. Regarding current trading prices, HLN is priced at $10.45, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HLN's ROE is +0.09%, compared to DCPH's ROE of -0.52%. Regarding short-term risk, HLN is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs EMBCV Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, EMBCV has a market cap of 1.91B. Regarding current trading prices, HLN is priced at $10.45, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HLN's ROE is +0.09%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, HLN is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SUPN Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SUPN has a market cap of 1.81B. Regarding current trading prices, HLN is priced at $10.45, while SUPN trades at $32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SUPN's P/E ratio is 24.45. In terms of profitability, HLN's ROE is +0.09%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BHC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, BHC has a market cap of 1.73B. Regarding current trading prices, HLN is priced at $10.45, while BHC trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas BHC's P/E ratio is -38.96. In terms of profitability, HLN's ROE is +0.09%, compared to BHC's ROE of +0.05%. Regarding short-term risk, HLN is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BGM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, BGM has a market cap of 1.69B. Regarding current trading prices, HLN is priced at $10.45, while BGM trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas BGM's P/E ratio is -57.95. In terms of profitability, HLN's ROE is +0.09%, compared to BGM's ROE of N/A. Regarding short-term risk, HLN is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TARO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TARO has a market cap of 1.62B. Regarding current trading prices, HLN is priced at $10.45, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TARO's P/E ratio is 30.05. In terms of profitability, HLN's ROE is +0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HLN is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs INDV Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, INDV has a market cap of 1.40B. Regarding current trading prices, HLN is priced at $10.45, while INDV trades at $11.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas INDV's P/E ratio is -223.80. In terms of profitability, HLN's ROE is +0.09%, compared to INDV's ROE of -0.01%. Regarding short-term risk, HLN is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ANIP Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ANIP has a market cap of 1.34B. Regarding current trading prices, HLN is priced at $10.45, while ANIP trades at $62.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ANIP's P/E ratio is -59.62. In terms of profitability, HLN's ROE is +0.09%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, HLN is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DVAX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, DVAX has a market cap of 1.16B. Regarding current trading prices, HLN is priced at $10.45, while DVAX trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas DVAX's P/E ratio is -19.24. In terms of profitability, HLN's ROE is +0.09%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, HLN is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AMPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, AMPH has a market cap of 1.13B. Regarding current trading prices, HLN is priced at $10.45, while AMPH trades at $23.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas AMPH's P/E ratio is 7.80. In terms of profitability, HLN's ROE is +0.09%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, HLN is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PCRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, PCRX has a market cap of 1.08B. Regarding current trading prices, HLN is priced at $10.45, while PCRX trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas PCRX's P/E ratio is -10.88. In terms of profitability, HLN's ROE is +0.09%, compared to PCRX's ROE of -0.12%. Regarding short-term risk, HLN is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PAHC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, PAHC has a market cap of 996.39M. Regarding current trading prices, HLN is priced at $10.45, while PAHC trades at $24.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas PAHC's P/E ratio is 51.25. In terms of profitability, HLN's ROE is +0.09%, compared to PAHC's ROE of +0.07%. Regarding short-term risk, HLN is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs HROW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, HROW has a market cap of 964.10M. Regarding current trading prices, HLN is priced at $10.45, while HROW trades at $26.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas HROW's P/E ratio is -53.61. In terms of profitability, HLN's ROE is +0.09%, compared to HROW's ROE of -0.36%. Regarding short-term risk, HLN is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs COLL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, COLL has a market cap of 957.84M. Regarding current trading prices, HLN is priced at $10.45, while COLL trades at $29.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas COLL's P/E ratio is 16.02. In terms of profitability, HLN's ROE is +0.09%, compared to COLL's ROE of +0.19%. Regarding short-term risk, HLN is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PETQ Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, PETQ has a market cap of 919.17M. Regarding current trading prices, HLN is priced at $10.45, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HLN's ROE is +0.09%, compared to PETQ's ROE of +0.06%. Regarding short-term risk, HLN is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs AVDL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, AVDL has a market cap of 872.59M. Regarding current trading prices, HLN is priced at $10.45, while AVDL trades at $9.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas AVDL's P/E ratio is -17.71. In terms of profitability, HLN's ROE is +0.09%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, HLN is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CRON Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, CRON has a market cap of 786.25M. Regarding current trading prices, HLN is priced at $10.45, while CRON trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas CRON's P/E ratio is 18.55. In terms of profitability, HLN's ROE is +0.09%, compared to CRON's ROE of +0.04%. Regarding short-term risk, HLN is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs EMBC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, EMBC has a market cap of 730.53M. Regarding current trading prices, HLN is priced at $10.45, while EMBC trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas EMBC's P/E ratio is 12.63. In terms of profitability, HLN's ROE is +0.09%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, HLN is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs EOLS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, EOLS has a market cap of 653.14M. Regarding current trading prices, HLN is priced at $10.45, while EOLS trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas EOLS's P/E ratio is -12.51. In terms of profitability, HLN's ROE is +0.09%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, HLN is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BDSI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, BDSI has a market cap of 577.05M. Regarding current trading prices, HLN is priced at $10.45, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HLN's ROE is +0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HLN is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs TLRY Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TLRY has a market cap of 454.53M. Regarding current trading prices, HLN is priced at $10.45, while TLRY trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TLRY's P/E ratio is -0.41. In terms of profitability, HLN's ROE is +0.09%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, HLN is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ORGO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ORGO has a market cap of 399.59M. Regarding current trading prices, HLN is priced at $10.45, while ORGO trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ORGO's P/E ratio is -315.00. In terms of profitability, HLN's ROE is +0.09%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, HLN is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs KMDA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, KMDA has a market cap of 396.21M. Regarding current trading prices, HLN is priced at $10.45, while KMDA trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas KMDA's P/E ratio is 27.56. In terms of profitability, HLN's ROE is +0.09%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SIGA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SIGA has a market cap of 390.58M. Regarding current trading prices, HLN is priced at $10.45, while SIGA trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SIGA's P/E ratio is 4.56. In terms of profitability, HLN's ROE is +0.09%, compared to SIGA's ROE of +0.33%. Regarding short-term risk, HLN is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TKNO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TKNO has a market cap of 360.19M. Regarding current trading prices, HLN is priced at $10.45, while TKNO trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TKNO's P/E ratio is -11.82. In terms of profitability, HLN's ROE is +0.09%, compared to TKNO's ROE of -0.32%. Regarding short-term risk, HLN is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ZYBT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ZYBT has a market cap of 351.17M. Regarding current trading prices, HLN is priced at $10.45, while ZYBT trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ZYBT's P/E ratio is 123.50. In terms of profitability, HLN's ROE is +0.09%, compared to ZYBT's ROE of N/A. Regarding short-term risk, HLN is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SNDL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SNDL has a market cap of 339.64M. Regarding current trading prices, HLN is priced at $10.45, while SNDL trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SNDL's P/E ratio is -4.40. In terms of profitability, HLN's ROE is +0.09%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, HLN is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs EBS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, EBS has a market cap of 319.15M. Regarding current trading prices, HLN is priced at $10.45, while EBS trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas EBS's P/E ratio is -1.63. In terms of profitability, HLN's ROE is +0.09%, compared to EBS's ROE of -0.27%. Regarding short-term risk, HLN is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ALIM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ALIM has a market cap of 301.29M. Regarding current trading prices, HLN is priced at $10.45, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HLN's ROE is +0.09%, compared to ALIM's ROE of -0.34%. Regarding short-term risk, HLN is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs ACB Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ACB has a market cap of 283.20M. Regarding current trading prices, HLN is priced at $10.45, while ACB trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ACB's P/E ratio is 25.80. In terms of profitability, HLN's ROE is +0.09%, compared to ACB's ROE of -0.06%. Regarding short-term risk, HLN is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LNDC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, LNDC has a market cap of 263.63M. Regarding current trading prices, HLN is priced at $10.45, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HLN's ROE is +0.09%, compared to LNDC's ROE of -0.65%. Regarding short-term risk, HLN is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CGC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, CGC has a market cap of 262.58M. Regarding current trading prices, HLN is priced at $10.45, while CGC trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas CGC's P/E ratio is -0.40. In terms of profitability, HLN's ROE is +0.09%, compared to CGC's ROE of -0.88%. Regarding short-term risk, HLN is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LFCR Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, LFCR has a market cap of 257.33M. Regarding current trading prices, HLN is priced at $10.45, while LFCR trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas LFCR's P/E ratio is -4.73. In terms of profitability, HLN's ROE is +0.09%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, HLN is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TYHT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TYHT has a market cap of 229.17M. Regarding current trading prices, HLN is priced at $10.45, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HLN's ROE is +0.09%, compared to TYHT's ROE of -0.84%. Regarding short-term risk, HLN is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AQST Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, AQST has a market cap of 227.44M. Regarding current trading prices, HLN is priced at $10.45, while AQST trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas AQST's P/E ratio is -4.49. In terms of profitability, HLN's ROE is +0.09%, compared to AQST's ROE of +1.07%. Regarding short-term risk, HLN is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs REPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, REPH has a market cap of 177.42M. Regarding current trading prices, HLN is priced at $10.45, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas REPH's P/E ratio is -8.04. In terms of profitability, HLN's ROE is +0.09%, compared to REPH's ROE of -0.15%. Regarding short-term risk, HLN is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs OGI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, OGI has a market cap of 156.56M. Regarding current trading prices, HLN is priced at $10.45, while OGI trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas OGI's P/E ratio is -3.54. In terms of profitability, HLN's ROE is +0.09%, compared to OGI's ROE of -0.18%. Regarding short-term risk, HLN is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ESPR Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ESPR has a market cap of 154.73M. Regarding current trading prices, HLN is priced at $10.45, while ESPR trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ESPR's P/E ratio is -2.79. In terms of profitability, HLN's ROE is +0.09%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, HLN is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DERM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, DERM has a market cap of 146.12M. Regarding current trading prices, HLN is priced at $10.45, while DERM trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas DERM's P/E ratio is -8.78. In terms of profitability, HLN's ROE is +0.09%, compared to DERM's ROE of -1.06%. Regarding short-term risk, HLN is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BIOA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, BIOA has a market cap of 143.04M. Regarding current trading prices, HLN is priced at $10.45, while BIOA trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas BIOA's P/E ratio is -0.60. In terms of profitability, HLN's ROE is +0.09%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, HLN is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs THTX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, THTX has a market cap of 120.47M. Regarding current trading prices, HLN is priced at $10.45, while THTX trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas THTX's P/E ratio is -37.43. In terms of profitability, HLN's ROE is +0.09%, compared to THTX's ROE of +0.16%. Regarding short-term risk, HLN is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SCTL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SCTL has a market cap of 116.13M. Regarding current trading prices, HLN is priced at $10.45, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HLN's ROE is +0.09%, compared to SCTL's ROE of -0.15%. Regarding short-term risk, HLN is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs PROC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, PROC has a market cap of 113.95M. Regarding current trading prices, HLN is priced at $10.45, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas PROC's P/E ratio is 1.53. In terms of profitability, HLN's ROE is +0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HLN is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs IRWD Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, IRWD has a market cap of 110.71M. Regarding current trading prices, HLN is priced at $10.45, while IRWD trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas IRWD's P/E ratio is -3.60. In terms of profitability, HLN's ROE is +0.09%, compared to IRWD's ROE of +0.01%. Regarding short-term risk, HLN is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs OPTN Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, OPTN has a market cap of 95.70M. Regarding current trading prices, HLN is priced at $10.45, while OPTN trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas OPTN's P/E ratio is -4.46. In terms of profitability, HLN's ROE is +0.09%, compared to OPTN's ROE of +0.39%. Regarding short-term risk, HLN is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs ZOM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ZOM has a market cap of 95.35M. Regarding current trading prices, HLN is priced at $10.45, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HLN's ROE is +0.09%, compared to ZOM's ROE of -0.28%. Regarding short-term risk, HLN is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CRDL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, CRDL has a market cap of 94.61M. Regarding current trading prices, HLN is priced at $10.45, while CRDL trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas CRDL's P/E ratio is -3.09. In terms of profitability, HLN's ROE is +0.09%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, HLN is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs GRVI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, GRVI has a market cap of 88.91M. Regarding current trading prices, HLN is priced at $10.45, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HLN's ROE is +0.09%, compared to GRVI's ROE of -2.44%. Regarding short-term risk, HLN is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CPIX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, CPIX has a market cap of 77.66M. Regarding current trading prices, HLN is priced at $10.45, while CPIX trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas CPIX's P/E ratio is -12.09. In terms of profitability, HLN's ROE is +0.09%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, HLN is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs INCR Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, INCR has a market cap of 72.16M. Regarding current trading prices, HLN is priced at $10.45, while INCR trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas INCR's P/E ratio is -3.73. In terms of profitability, HLN's ROE is +0.09%, compared to INCR's ROE of -0.07%. Regarding short-term risk, HLN is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ZYNE Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ZYNE has a market cap of 70.12M. Regarding current trading prices, HLN is priced at $10.45, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HLN's ROE is +0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HLN is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SSIC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SSIC has a market cap of 66.72M. Regarding current trading prices, HLN is priced at $10.45, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HLN's ROE is +0.09%, compared to SSIC's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs VLNS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, VLNS has a market cap of 61.46M. Regarding current trading prices, HLN is priced at $10.45, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HLN's ROE is +0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, HLN is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ASRT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ASRT has a market cap of 58.30M. Regarding current trading prices, HLN is priced at $10.45, while ASRT trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ASRT's P/E ratio is -2.65. In terms of profitability, HLN's ROE is +0.09%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, HLN is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs JUPW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, JUPW has a market cap of 49.33M. Regarding current trading prices, HLN is priced at $10.45, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HLN's ROE is +0.09%, compared to JUPW's ROE of -0.06%. Regarding short-term risk, HLN is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs QLI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, QLI has a market cap of 38.68M. Regarding current trading prices, HLN is priced at $10.45, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas QLI's P/E ratio is -4.92. In terms of profitability, HLN's ROE is +0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HLN is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs SCYX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SCYX has a market cap of 37.66M. Regarding current trading prices, HLN is priced at $10.45, while SCYX trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SCYX's P/E ratio is -2.19. In terms of profitability, HLN's ROE is +0.09%, compared to SCYX's ROE of -0.34%. Regarding short-term risk, HLN is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs RMTI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, RMTI has a market cap of 36.57M. Regarding current trading prices, HLN is priced at $10.45, while RMTI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas RMTI's P/E ratio is -35.67. In terms of profitability, HLN's ROE is +0.09%, compared to RMTI's ROE of -0.02%. Regarding short-term risk, HLN is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs HEXO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, HEXO has a market cap of 31.24M. Regarding current trading prices, HLN is priced at $10.45, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HLN's ROE is +0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HLN is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SXTC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SXTC has a market cap of 27.94M. Regarding current trading prices, HLN is priced at $10.45, while SXTC trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SXTC's P/E ratio is 0.02. In terms of profitability, HLN's ROE is +0.09%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, HLN is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CYTH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, CYTH has a market cap of 23.59M. Regarding current trading prices, HLN is priced at $10.45, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HLN's ROE is +0.09%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, HLN is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs EGRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, EGRX has a market cap of 22.68M. Regarding current trading prices, HLN is priced at $10.45, while EGRX trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas EGRX's P/E ratio is 2.06. In terms of profitability, HLN's ROE is +0.09%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, HLN is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs KALA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, KALA has a market cap of 22.45M. Regarding current trading prices, HLN is priced at $10.45, while KALA trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas KALA's P/E ratio is -0.34. In terms of profitability, HLN's ROE is +0.09%, compared to KALA's ROE of -3.89%. Regarding short-term risk, HLN is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DRRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, DRRX has a market cap of 20.46M. Regarding current trading prices, HLN is priced at $10.45, while DRRX trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas DRRX's P/E ratio is -1.10. In terms of profitability, HLN's ROE is +0.09%, compared to DRRX's ROE of -1.41%. Regarding short-term risk, HLN is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs QNTM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, QNTM has a market cap of 19.36M. Regarding current trading prices, HLN is priced at $10.45, while QNTM trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas QNTM's P/E ratio is -0.64. In terms of profitability, HLN's ROE is +0.09%, compared to QNTM's ROE of N/A. Regarding short-term risk, HLN is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TXMD Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TXMD has a market cap of 17.59M. Regarding current trading prices, HLN is priced at $10.45, while TXMD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TXMD's P/E ratio is -7.60. In terms of profitability, HLN's ROE is +0.09%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, HLN is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs FLGC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, FLGC has a market cap of 16.42M. Regarding current trading prices, HLN is priced at $10.45, while FLGC trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas FLGC's P/E ratio is -0.56. In terms of profitability, HLN's ROE is +0.09%, compared to FLGC's ROE of -3.31%. Regarding short-term risk, HLN is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ACRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ACRX has a market cap of 14.58M. Regarding current trading prices, HLN is priced at $10.45, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HLN's ROE is +0.09%, compared to ACRX's ROE of -0.40%. Regarding short-term risk, HLN is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SISI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, SISI has a market cap of 14.41M. Regarding current trading prices, HLN is priced at $10.45, while SISI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas SISI's P/E ratio is -0.01. In terms of profitability, HLN's ROE is +0.09%, compared to SISI's ROE of -0.84%. Regarding short-term risk, HLN is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PRPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, PRPH has a market cap of 14.24M. Regarding current trading prices, HLN is priced at $10.45, while PRPH trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas PRPH's P/E ratio is -0.14. In terms of profitability, HLN's ROE is +0.09%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, HLN is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs GELS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, GELS has a market cap of 13.59M. Regarding current trading prices, HLN is priced at $10.45, while GELS trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas GELS's P/E ratio is -6.00. In terms of profitability, HLN's ROE is +0.09%, compared to GELS's ROE of N/A. Regarding short-term risk, HLN is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs COSM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, COSM has a market cap of 13.34M. Regarding current trading prices, HLN is priced at $10.45, while COSM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas COSM's P/E ratio is -0.42. In terms of profitability, HLN's ROE is +0.09%, compared to COSM's ROE of -0.51%. Regarding short-term risk, HLN is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BFRIW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, BFRIW has a market cap of 13.20M. Regarding current trading prices, HLN is priced at $10.45, while BFRIW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas BFRIW's P/E ratio is -0.11. In terms of profitability, HLN's ROE is +0.09%, compared to BFRIW's ROE of -4.60%. Regarding short-term risk, HLN is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TLPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, TLPH has a market cap of 10.66M. Regarding current trading prices, HLN is priced at $10.45, while TLPH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas TLPH's P/E ratio is -1.04. In terms of profitability, HLN's ROE is +0.09%, compared to TLPH's ROE of -1.11%. Regarding short-term risk, HLN is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AGRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, AGRX has a market cap of 10.43M. Regarding current trading prices, HLN is priced at $10.45, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HLN's ROE is +0.09%, compared to AGRX's ROE of +1.04%. Regarding short-term risk, HLN is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs NLTX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, NLTX has a market cap of 8.20M. Regarding current trading prices, HLN is priced at $10.45, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HLN's ROE is +0.09%, compared to NLTX's ROE of -0.09%. Regarding short-term risk, HLN is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AYTU Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, AYTU has a market cap of 8.08M. Regarding current trading prices, HLN is priced at $10.45, while AYTU trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas AYTU's P/E ratio is -0.63. In terms of profitability, HLN's ROE is +0.09%, compared to AYTU's ROE of -0.18%. Regarding short-term risk, HLN is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LCI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, LCI has a market cap of 7.38M. Regarding current trading prices, HLN is priced at $10.45, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas LCI's P/E ratio is -0.04. In terms of profitability, HLN's ROE is +0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HLN is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BGXX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, BGXX has a market cap of 7.26M. Regarding current trading prices, HLN is priced at $10.45, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas BGXX's P/E ratio is -0.76. In terms of profitability, HLN's ROE is +0.09%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, HLN is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ADMP Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, ADMP has a market cap of 7.25M. Regarding current trading prices, HLN is priced at $10.45, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas ADMP's P/E ratio is -0.08. In terms of profitability, HLN's ROE is +0.09%, compared to ADMP's ROE of +0.00%. Regarding short-term risk, HLN is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CPHI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, CPHI has a market cap of 6.85M. Regarding current trading prices, HLN is priced at $10.45, while CPHI trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas CPHI's P/E ratio is -0.78. In terms of profitability, HLN's ROE is +0.09%, compared to CPHI's ROE of -0.63%. Regarding short-term risk, HLN is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BFRI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 47.13B. In comparison, BFRI has a market cap of 6.68M. Regarding current trading prices, HLN is priced at $10.45, while BFRI trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 24.88, whereas BFRI's P/E ratio is -0.22. In terms of profitability, HLN's ROE is +0.09%, compared to BFRI's ROE of -4.60%. Regarding short-term risk, HLN is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.